Turner Gas Company. Our products include wholesale propane, natural gas liquids, chemicals, and crude. Turner Gas Company is family- owned and has successfully served customers for over 7. We are the market leader in energy and chemical transportation, marketing and logistics throughout the Western & Central United States. Video News - CNN. Chat with us in Facebook Messenger. Find out what's happening in the world as it unfolds. Flashcard Machine - create, study and share online flash cards It's important to control phosphorus levels for dogs with kidney disease. The goal is to maintain blood phosphorus levels below 4.5 for dogs with. Complete OFO Version 2015 OFO Code Description 2015-1 MANAGERS Managers plan, direct, coordinate and evaluate the overall activities of enterprises, governments and. A Texas Co- Packer: Home. FDA prescribing information, side effects and uses. Forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Forteo reduces the risk of vertebral and nonvertebral fractures . Consequently, use of the drug for more than 2 years during a patient's lifetime is not recommended. Multi- dose prefilled delivery device (pen) for subcutaneous injection containing 2. In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration . Forteo should not be prescribed for patients at increased baseline risk of osteosarcoma. Patients should be encouraged to enroll in the voluntary Forteo Patient Registry, which is designed to collect information about any potential risk of osteosarcoma in patients who have taken Forteo. Enrollment information can be obtained by calling 1- 8. Forteoregistry. rti. The safety and efficacy of Forteo have not been evaluated beyond 2 years of treatment. Consequently, use of the drug for more than 2 years during a patients' lifetime is not recommended. Patients with bone metastases or a history of skeletal malignancies should not be treated with Forteo. Patients with metabolic bone diseases other than osteoporosis should not be treated with Forteo. Forteo has not been studied in patients with pre- existing hypercalcemia. These patients should not be treated with Forteo because of the possibility of exacerbating hypercalcemia. Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with Forteo. In clinical trials, the frequency of urolithiasis was similar in patients treated with Forteo and placebo. However, Forteo has not been studied in patients with active urolithiasis. If active urolithiasis or pre- existing hypercalciuria are suspected, measurement of urinary calcium excretion should be considered. Forteo should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition. Forteo should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur. In short- term clinical pharmacology studies with teriparatide, transient episodes of symptomatic orthostatic hypotension were observed in 5% of patients. 15 Gauge Needle Dialysis Diet GuidelinesTypically, an event began within 4 hours of dosing and spontaneously resolved within a few minutes to a few hours. When transient orthostatic hypotension occurred, it happened within the first several doses, it was relieved by placing the person in a reclining position, and it did not preclude continued treatment. Hypercalcemia may predispose patients to digitalis toxicity. Because Forteo transiently increases serum calcium, patients receiving digoxin should use Forteo with caution . The median durations of the trials were 1. Forteo and 6. 91 patients to placebo. All patients received 1. IU of vitamin D supplementation per day. The incidence of all cause mortality was 1% in the Forteo group and 1% in the placebo group. The incidence of serious adverse events was 1. Forteo patients and 1. Study Flashcards On Nursing Mnemonics Part 1 at Cram.com. Quickly memorize the terms, phrases and much more. Cram.com makes it easy to get the grade you want! Our co-packing suites are climate controlled and segregated from each. Early discontinuation due to adverse events occurred in 7% of Forteo patients and 6% of placebo patients. Table 1 lists adverse events from the two principal osteoporosis trials in men and postmenopausal women that occurred in . Percentage of Patients with Adverse Events Reported by at Least 2% of Forteo- Treated Patients and in More Forteo- Treated Patients than Placebo- Treated Patients from the Two Principal Osteoporosis Trials in Women and Men. Adverse Events are Shown Without Attribution of Causality. Forteo. N=6. 91. Placebo. N=6. 91 Event Classification(%)(%) Body as a Whole Pain. Headache. 7. 5. 7. Asthenia. 8. 7. 6. Neck pain. 3. 0. 2. Cardiovascular Hypertension. Angina pectoris. 2. Syncope. 2. 6. 1. Digestive System Nausea. Constipation. 5. 4. Diarrhea. 5. 1. 4. Dyspepsia. 5. 2. 4. Vomiting. 3. 0. 2. Gastrointestinal disorder. Tooth disorder. 2. Musculoskeletal Arthralgia. Leg cramps. 2. 6. Nervous System Dizziness. Depression. 4. 1. Insomnia. 4. 3. 3. Vertigo. 3. 8. 2. Respiratory System Rhinitis. Cough increased. 6. Pharyngitis. 5. 5. Dyspnea. 3. 6. 2. Pneumonia. 3. 9. 3. Skin and Appendages Rash. Sweating. 2. 2. 1. Immunogenicity — In the clinical trial, antibodies that cross- reacted with teriparatide were detected in 3% of women (1. Forteo. Generally, antibodies were first detected following 1. There was no evidence of hypersensitivity reactions or allergic reactions among these patients. Antibody formation did not appear to have effects on serum calcium, or on bone mineral density (BMD) response. Laboratory Findings. Serum Calcium — Forteo transiently increased serum calcium, with the maximal effect observed at approximately 4 to 6 hours post- dose. Serum calcium measured at least 1. In clinical trials, the frequency of at least 1 episode of transient hypercalcemia in the 4 to 6 hours after Forteo administration was increased from 2% of women and none of the men treated with placebo to 1. Forteo. The number of patients treated with Forteo whose transient hypercalcemia was verified on consecutive measurements was 3% of women and 1% of men. Urinary Calcium — Forteo increased urinary calcium excretion, but the frequency of hypercalciuria in clinical trials was similar for patients treated with Forteo and placebo . In clinical trials, 3% of Forteo patients had serum uric acid concentrations above the upper limit of normal compared with 1% of placebo patients. However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis. Renal Function — No clinically important adverse renal effects were observed in clinical studies. Assessments included creatinine clearance; measurements of blood urea nitrogen (BUN), creatinine, and electrolytes in serum; urine specific gravity and p. H; and examination of urine sediment. Studies in Men and Women with Glucocorticoid- Induced Osteoporosis. The safety of Forteo in the treatment of men and women with glucocorticoid- induced osteoporosis was assessed in a randomized, double- blind, active- controlled trial of 4. The duration of the trial was 1. Forteo and 2. 14 patients exposed to oral daily bisphosphonate (active control). All patients received 1. IU of vitamin D supplementation per day. The incidence of all cause mortality was 4% in the Forteo group and 6% in the active control group. The incidence of serious adverse events was 2. Forteo patients and 1. Forteo, 1% active control). Early discontinuation because of adverse events occurred in 1. Forteo patients and 1. Forteo, 0% active control). Adverse events reported at a higher incidence in the Forteo group and with at least a 2% difference in Forteo- treated patients compared with active control- treated patients were: nausea (1. Postmarketing Experience. The following adverse reactions have been identified during postapproval use of Forteo. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Osteosarcoma: Cases of bone tumor and osteosarcoma have been reported rarely in the postmarketing period. The causality to Forteo use is unclear. Long term osteosarcoma surveillance studies are ongoing . However, because Forteo may transiently increase serum calcium, Forteo should be used with caution in patients taking digoxin . The effect of coadministration of a higher dose of hydrochlorothiazide with teriparatide on serum calcium levels has not been studied . In animal studies, teriparatide increased skeletal deviations and variations in mouse offspring at doses more than 6. Forteo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In animal studies, pregnant mice received teriparatide during organogenesis at subcutaneous doses 8 to 2. When pregnant rats received subcutaneous teriparatide during organogenesis at doses 1. In a perinatal/postnatal study, pregnant rats received subcutaneous teriparatide from organogenesis through lactation. Mild growth retardation in female offspring at doses . Mild growth retardation in male offspring and reduced motor activity in both male and female offspring occurred at maternal doses 5. There were no developmental or reproductive effects in mice or rats at doses 8 or 1. Exposure multiples were normalized based on body surface area (mcg/m. Actual animal doses: mice (3. Nursing Mothers. It is not known whether teriparatide is excreted in human milk. Because of the potential for tumorigenicity shown for teriparatide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use. The safety and efficacy of Forteo have not been established in any pediatric population. Forteo should not be prescribed in patients at an increased baseline risk of osteosarcoma which include pediatric and young adult patients with open epiphyses. Therefore, Forteo is not indicated for use in pediatric or young adult patients with open epiphyses . Of the patients receiving Forteo in the osteoporosis trial of 4. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Hepatic Impairment. No studies have been performed in patients with hepatic impairment. Maximum serum concentration of teriparatide was not increased . Teriparatide has been administered in single doses of up to 1.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
August 2017
Categories |